Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 701–800 of 1,000
Rotin, L. E., Gronda, M., MacLean, N., Hurren, R., Wang, X., Lin, F.-H., Wrana, J. L., Datti, A., Barber, D. L., Minden, M. D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6409 · Cited by 26
“BTK mRNA expression was examined in 267 patients with AML [46].”
BackgroundTong, J., Helmy, M., Cavalli, F. M. G., Jin, L. L., St‐Germain, J. R., Karisch, R., Taylor, P. P., Minden, M. D., Taylor, M. D., Neel, B. G., et al. (2017) · PROTEOMICS · doi:10.1002/pmic.201600361 · Cited by 23
“Gene expression signatures have been suggested for AML [6,7].”
BackgroundSmith, M. L., & McKerrell, T. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch3 · Cited by 22
WT1 monitoring in core binding factor AML: Comparison with specific chimeric products
Lasa, A., Carricondo, M., Estivill, C., Bussaglia, E., Gich, I. J., Brunet, S., Aventin, A. M., Sierra, J., & Nomdedeu, J. F. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.03.046 · Cited by 22
Cross-generation and cross-laboratory predictions of Affymetrix microarrays by rank-based methods
Liu, H., Chen, C., Liu, Y., Chu, C.-B., Liang, D., Shih, L., & Lin, C. (2007) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2007.11.005 · Cited by 22
TMABoost: An Integrated System for Comprehensive Management of Tissue Microarray Data
Demichelis, F., Sboner, A., Barbareschi, M., & Dell’Anna, R. (2006) · IEEE Transactions on Information Technology in Biomedicine · doi:10.1109/titb.2005.855540 · Cited by 22
Verhaak, R. G. W., & Valk, P. J. M. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_5 · Cited by 21
“Ideally these studies should be carried out using a representative AML patient-cohort, i.e., without excluding any subtype of AML, to ascertain that subtypes are predicted accurately [ 72 , 10].”
BackgroundMethodResultSelf-citationUsing microarrays to predict resistance to chemotherapy in cancer patients
Lee, C.-H., & Macgregor, P. F. (2004) · Pharmacogenomics · doi:10.1517/14622416.5.6.611 · Cited by 22
Metzeler, K. H., & Bloomfield, C. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_12 · Cited by 24
Genomic Assessment of Pediatric Acute Leukemia
Mullighan, C. G., Flotho, C., & Downing, J. R. (2005) · The Cancer Journal · doi:10.1097/00130404-200507000-00003 · Cited by 23
Common gene expression signatures in t(8;21)‐ and inv(16)‐acute myeloid leukaemia
Ichikawa, H., Tanabe, K., Mizushima, H., Hayashi, Y., Mizutani, S., Ishii, E., Hongo, T., Kikuchi, A., & Satake, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06310.x · Cited by 24
“To do so we employed another set of microarray data from AML patients reported by Valk et al (2004).”
BackgroundMethodResultInfluentialNess, S. A. (2006) · Humana Press eBooks · doi:10.1385/1-59259-964-8:13 · Cited by 22
Strategies in the treatment of acute myeloid leukemia.
Löwenberg, B. (2004) · PubMed · Cited by 22
Self-citationIs there a niche for DNA microarrays in molecular diagnostics?
Jordan, B. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.74 · Cited by 23
Meis2 as a critical player in MN1-induced leukemia
Lai, C. K., Norddahl, G. L., Maetzig, T., Rosten, P. M., Lohr, T., Milde, L. S., von Krosigk, N., Docking, R., Heuser, M., Karsan, A., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.86 · Cited by 22
Jentzsch, M., Bill, M., Grimm, J., Schulz, J. C., Beinicke, S., Häntschel, J., Goldmann, K., Pönisch, W., Franke, G., Vučinić, V., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000167 · Cited by 23
Bacher, U., Kohlmann, A., & Haferlach, T. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.002 · Cited by 21
Comparison of Feature Selection Methods for Cross-Laboratory Microarray Analysis
Liu, H., Peng, P.-C., Hsieh, T., Yeh, T., Lin, C., Chen, C., Hou, J., Shih, L., & Liang, D. (2013) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2013.70 · Cited by 26
“AML-1 from Valk et al. [27] and AML-3 from Gutiérrez et al. [28] are adult studies, but AML-2 from Ross et al. [29] is a childhood study.”
BackgroundThe significance of low PU.1 expression in patients with acute promyelocytic leukemia
Zhu, X., Zhang, H., Qian, M., Zhao, X., Yang, W., Wang, P., Zhang, J., & Wang, K. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-22 · Cited by 21
“62 46,XX,t(15;17)(q22;q12)[10]/ 46,XX[11]”
MethodInfluentialInhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics
Reikvam, H. (2020) · Cells · doi:10.3390/cells9071677 · Cited by 22
“GEP in AML is a well-established methodological strategy with clinical relevance, it reflects cytogenetic and molecular genetic subclassifications, and has a prognostic impact [41,42].”
BackgroundRollins‐Raval, M. A., & Roth, C. G. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04175.x · Cited by 21
CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias
Chakhachiro, Z. I., Zuo, Z., Aladily, T. N., Kantarjian, H. M., Cortes, J. E., Alayed, K. M., Nguyen, M. H., Medeiros, L. J., & Bueso-Ramos, C. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcpg8xh7zonakxk · Cited by 21
“2)[17] 28 AML with t(15;17)(q24.”
Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material
Gravendeel, L. A. M., de Rooi, J. J., Eilers, P. H. C., van den Bent, M. J., Smitt, P. A. E. S., & French, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.547 · Cited by 25
“Gene expression profiling of cancer offers an accurate and objective method for classifying cancer subtypes (Sorlie et al, 2001; Valk et al, 2004).”
MethodMN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML
Larmonie, N. S. D., Arentsen-Peters, T. C. J. M., Obulkasim, A., Valerio, D. G., Sonneveld, E., Oorschot, A. A. D.-V., de Haas, V., Reinhardt, D., Zimmermann, M., Trka, J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.293 · Cited by 23
Identification of gene expression signatures for molecular classification in human leukemia cells
Song, J. Y., Kim, H., Lee, C., Kim, S., Hwang, S. H., & Kim, T. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.57 · Cited by 21
Engen, C., Hellesøy, M., Grob, T., Hinai, A. S. A. A., Brendehaug, A., Wergeland, L., Bedringaas, S. L., Hovland, R., Valk, P. J. M., & Gjertsen, B. T. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12961 · Cited by 21
Self-citationAdamo, A., Chin, P. S., Keane, P., Assi, S. A., Potluri, S., Kellaway, S. G., Coleman, D., Ames, L., Ptasinska, A., Delwel, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01744-5 · Cited by 23
“Different mutations lead to different disease phenotypes, gene expression profiles and clinical outcomes(3).”
InfluentialSelf-citationSingle-cell transcriptome analyses reveal critical roles of RNA splicing during leukemia progression
Wu, B., Chen, X., Pan, X., Deng, X., Li, S., Wang, Z., Wang, J., Liao, D., Xu, J., Chen, M., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002088 · Cited by 21
“Low-risk, high-risk MDS and MDS_AML patient data GSM2430698 [15] and AML patient data GSE1159 [35] were downloaded from the GEO database.”
Epigenetics and cancer, 2nd IARC meeting, Lyon, France, 6 and 7 December 2007
Lambert, M.-P., & Herceg, Z. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.03.005 · Cited by 20
“…these processes to cancer were discussed by Tycko, including the probable alteration of non-island sequences in tumours and how stable methylation changes are correlated with gene expression and the gain of aberrant DNA methylation in specific malignancies (e.g., Wilms tumours) (Valk et al., 2004).”
BackgroundMicro RNA control of myelopoiesis and the differentiation block in acute myeloid leukaemia
Palma, C. A., Tonna, E., David, D. F., & Lutherborrow, M. A. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01514.x · Cited by 21
van der Valk, M. A., Delwel, R., Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., & Peter, J. M. (2009) · Cited by 20
Self-citationMughal, M. K., Akhter, A., Street, L. E., Pournazari, P., Shabani‐Rad, M., & Mansoor, A. (2016) · Hematological Oncology · doi:10.1002/hon.2279 · Cited by 20
“Initial studies analysing MYC on RNA-based array platform produced controversial results [12,13].”
BackgroundResultHigh level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome
Xu, L., Guo, Y., Yan, W., Cen, J., Niu, Y., Yan, Q., He, H., Chen, C.-S., & Hu, S. (2017) · EXCLI journal · doi:10.17179/excli2016-707 · Cited by 26
“Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy with increasing identified cytogenetic and molecular abnormalities (Valk et al., 2004).”
BackgroundTorrebadell, M., Díaz‐Beyá, M., Kalko, S. G., Pratcorona, M., Nomdedeu, J. F., Navarro, A., Gel, B., Brunet, S., Sierra, J., Camós, M., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1422859 · Cited by 20
Verhagen, H. J. M. P., van Gils, N., Martiáñez, T., van Rhenen, A., Rutten, A. P., Denkers, F., de Leeuw, D. C., Smit, M. A., Tsui, M.-L., Klootwijk, L. L. E. D. V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.062 · Cited by 20
Data-driven characterization of molecular phenotypes across heterogeneous sample collections
Mehtonen, J., Pölönen, P., Häyrynen, S., Dufva, O., Lin, J., Liuksiala, T., Granberg, K. J., Lohi, O., Hautamäki, V., Nykter, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz281 · Cited by 22
“These molecular phenotypes that we found to distinguish clusters of fusion gene-negative samples could be identified from each dataset, demonstrating that the molecular subtypes found are robust, comparable to the fusion gene clusters distinguished in previous classifications (29,30).”
BackgroundResultSun, X., Zhang, W., Ramdas, L., Stivers, D. N., Jones, D. M., Kantarjian, H. M., Estey, E. H., Vadhan‐Raj, S., Medeiros, L. J., & Bueso-Ramos, C. (2007) · Modern Pathology · doi:10.1038/modpathol.3800829 · Cited by 20
“Most acute myeloid leukemia studies to date, however, have focused on the diagnosis and classification of closely related groups of malignancies”
BackgroundNishikawa, S., Arai, S., Masamoto, Y., Kagoya, Y., Toya, T., Watanabe‐Okochi, N., & Kurokawa, M. (2014) · Blood · doi:10.1182/blood-2013-12-546275 · Cited by 20
The Foundations of Genomic and Personalized Medicine
Ginsburg, G. S., & Willard, H. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374934-5.00001-5 · Cited by 25
Gene expression profiling in acute myeloid leukaemia (AML)
Bacher, U., Kohlmann, A., Haferlach, C., & Haferlach, T. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.04.003 · Cited by 20
Hellesøy, M., Engen, C., Grob, T., Löwenberg, B., Valk, P. J. M., & Gjertsen, B. T. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13035 · Cited by 23
Self-citationRubino, V., Hüppi, M., Höpner, S., Tortola, L., Schnüriger, N., Legenne, H., Taylor, L., Voggensperger, S., Keller, I., Bruggmann, R., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101826 · Cited by 19
Fu, L. N., Shi, J., Hu, K., Wang, J., Wang, W., & Ke, X. (2015) · Oncotarget · doi:10.18632/oncotarget.3519 · Cited by 19
“Both CN-AML (n = 116) and normal BM (n = 5) expressed MAPKBP1, although there was a relatively higher expression of MAPKBP1 in the former (P = 0.03) (GEO accession number GSE1159)[29].”
BackgroundInfluentialZhang, Y., Peng, L., Hu, T., Wan, Y., Ren, Y., Zhang, J., Wang, X., Zhou, Y., Yuan, W., Wang, Q., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.12.003 · Cited by 20
Poiré, X., Labopin, M., Polge, E., Blaise, D., Chevallier, P., Maertens, J. A., Deconinck, É., Forcade, É., Rambaldi, A., Baerlocher, G. M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25355 · Cited by 19
Molecular diagnosis of leukemia
Mason, J., & Griffiths, M. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.44 · Cited by 20
Low SMC1A protein expression predicts poor survival in acute myeloid leukemia
Krug (2010) · Oncology Reports · doi:10.3892/or_00000827 · Cited by 19
The Promise of Molecular Profiling for Cancer Identification and Treatment
Cross, D., & Burmester, J. K. (2004) · Clinical Medicine & Research · doi:10.3121/cmr.2.3.147 · Cited by 19
Oyan, A. M., Ånensen, N., Bø, T. H., Stordrange, L., Jonassen, I., Bruserud, Ø., Kalland, K., & Gjertsen, B. T. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-77 · Cited by 19
“Gene expression analysis may provide important prognostic information in the 50% of patients with standard risk for relapse due to normal karyotype [ 10 ,11].”
Progress and strategies for patients with relapsed and refractory acute myeloid leukemia
Litzow, M. R. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32801684ef · Cited by 19
Analysis of Microarray Experiments for Pulmonary Fibrosis
Davé, N. B., & Kaminski, N. (2005) · Humana Press eBooks · doi:10.1385/1-59259-940-0:333 · Cited by 19
Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing
Wang, J., Bhakta, N. H., Miller, V. A., Revsine, M., Litzow, M. R., Paietta, E. M., Fedoriw, Y., Roberts, K. G., Gu, Z., Mullighan, C. G., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00326 · Cited by 21
The ferroptosis landscape in acute myeloid leukemia
Ma, Z., Ye, W., Huang, X., Li, X., Li, F., Lin, X., Hu, C., Wang, J., Jin, J., Zhu, B., et al. (2023) · Aging · doi:10.18632/aging.205257 · Cited by 19
Ersvær, E., Hatfield, K. J., Reikvam, H., & Bruserud, Ø. (2010) · Bone Marrow Research · doi:10.1155/2011/570796 · Cited by 18
Bei, L., Shah, C., Wang, H., Huang, W., Platanias, L. C., & Eklund, E. A. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.49 · Cited by 20
Irandoust, M. I., Zárate, J. Á., Hubeek, I., van Beek, E. M., Schornagel, K., Broekhuizen, A. J. F., Akyuz, M., van de Loosdrecht, A. A., Delwel, R., Valk, P. J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052143 · Cited by 20
“We therefore evaluated a possible association between SIRPa and CD47 expression in different datasets [33,42,46], however we did not find any evidence for such an association in AML.”
InfluentialSelf-citationHirade, T., Abe, M., Onishi, C., Taketani, T., Yamaguchi, S., & Fukuda, S. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1908-8 · Cited by 18
“c The top panel indicates the percentage increase in RUNX1 mRNA in the patients with FLT3/ITD+ AML (N = 78) compared to FLT3/ITD− AML (N = 190) that are deposited in GSE1159 [30].”
BackgroundInfluentialNiavarani, A., Herold, T., Reyal, Y., Sauerland, M. C., Büchner, T., Hiddemann, W., Bohlander, S. K., Valk, P. J. M., & Bonnet, D. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13836 · Cited by 21
Self-citationKloos, A., Mintzas, K., Winckler, L., Gabdoulline, R. R., Alwie, Y., Jyotsana, N., Kattre, N., Schottmann, R., Scherr, M., Gupta, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0929-3 · Cited by 20
Grandits, A. M., Nguyen, C. H., Schlerka, A., Hackl, H., Sill, H., Etzler, J., Heyes, E. C., Stoiber, D., Grebien, F., Heller, G., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01224-2 · Cited by 18
Grandits, A. M., & Wieser, R. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.05.004 · Cited by 19
Gielen, S. C. J. P., Santegoets, L. A. M., Kühne, L. C., van IJcken, W. F. J., Boers-Sijmons, B., Hanifi‐Moghaddam, P., Helmerhorst, T. J. M., Blok, L. J., & Burger, C. W. (2007) · Reproductive Sciences · doi:10.1177/1933719107306872 · Cited by 21
“Using this method, only reliable results are generated for samples, with an average intensity value of 30 or more; therefore, all values between 0 and 30 were set to 30.(25) This procedure affected 46% of all intensity values, of which 98% were flagged as absent or marginal by GCOS, whereas 2% were flagged as present…”
MethodEpigenetic therapy as a novel approach for GFI136N-associated murine/human AML
Botezatu, L., Michel, L., Helness, A., Vadnais, C., Makishima, H., Hönes, J. M., Robert, F., Vaßen, L., Thivakaran, A., Al-Matary, Y. S., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.004 · Cited by 22
Wang, H., Chu, T., Han, S., Qi, J., Tang, Y., Qiu, H.-Y., Fu, C., Tang, X., Ruan, C., Wu, D., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.031 · Cited by 18
Drug delivery in acute myeloid leukemia
Kohlschütter, J., Michelfelder, S., & Trepel, M. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.6.653 · Cited by 18
“Some knowledge about the unique receptor profiles of AML cells may be gained from microarray gene expression profiling [61,62] .”
BackgroundCross-platform classification in microarray-based leukemia diagnostics.
Nilsson, B., Andersson, A., Johansson, M., & Fioretos, T. (2006) · PubMed · Cited by 18
Gracia-Maldonado, G., Clark, J. P., Burwinkel, M., Greenslade, B., Wunderlich, M., Salomonis, N., Leone, D. A., Gatti, E., Pierre, P., Kumar, A. R., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.257451 · Cited by 21
Masamoto, Y., Chiba, A., Mizuno, H., Hino, T., Hayashida, H., Sato, T., Bando, M., Shirahige, K., & Kurokawa, M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008018 · Cited by 19
“To further narrow the list, we utilized RNA-seq data obtained from BM cells transduced with EVI1(19) (Figure 2C) and human transcriptome data.(9) We chose the common genes as candidates: binding of EVI1, upregulation by EVI1 transduction, and positive correlation with EVI1 in human AML (Figure 2D-E).”
Mulet‐Lazaro, R., van Herk, S., Nuetzel, M., Sijs‐Szabó, A., Díaz, N., Kelly, K., Erpelinck-Verschueren, C. A. J., Schwarzfischer, L., Stanewsky, H., Ackermann, U., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49811-y · Cited by 19
Self-citationDistinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells
Phillips, J. L., Taberlay, P. C., Woodworth, A. M., Hardy, K., Brettingham‐Moore, K. H., Dickinson, J. L., & Holloway, A. F. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26197 · Cited by 17
“Altered expression of the ITGB4 gene has previously been reported in microarray studies examining cells containing the t(8;21) translocation (Ichikawa et al., 2006; Valk et al., 2004).”
BackgroundIdentification of a gene signature associated with radiotherapy and prognosis in gliomas
Li, S., Shi, J., Gao, H., Yuan, Y., Chen, Q., Zhao, Z., Wang, X., Li, B., Ming, L., Zhong, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21634 · Cited by 17
Ward, C., Cauchy, P., García, P., Frampton, J., Esteban, M. A., & Volpe, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-60480-x · Cited by 19
Chiarella, E., Aloisio, A., Scicchitano, S., Todoerti, K., Cosentino, E. G., Lico, D., Neri, A., Amodio, N., Bond, H. M., & Mesuraca, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910814 · Cited by 17
Reikvam, H., Oyan, A. M., Kalland, K., Hovland, R., Hatfield, K. J., & Bruserud, Ø. (2013) · Cell Proliferation · doi:10.1111/cpr.12057 · Cited by 17
Gene expression profiling for the diagnosis of acute leukaemia
Haferlach, T., Kohlmann, A., Bacher, U., Schnittger, S., Haferlach, C., & Kern, W. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603495 · Cited by 19
“Valk et al (2004) and Bullinger and Valk (2005) focused on AML with normal karyotype with respect to other molecular markers and prognosis.”
BackgroundMethodInfluentialDeKelver, R. C., Lewin, B., Weng, S., Yan, M., Biggs, J. R., & Zhang, D. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.815351 · Cited by 17
Functional analysis of the NUP98-CCDC28A fusion protein
Petit, A., Ragu, C., Soler, G., Ottolenghi, C., Schluth‐Bolard, C., Radford‐Weiss, I., Schneider‐Maunoury, S., Callebaut, I., Dastugue, N., Drabkin, H. A., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.047969 · Cited by 18
Ryotokuji, T., Yamaguchi, H., Ueki, T., Usuki, K., Kurosawa, S., Kobayashi, Y., Kawata, E., Tajika, K., Gomi, S., Kanda, J., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143073 · Cited by 18
“To improve the outcome of AML treatment, it is very important to establish a prognosis from cytogenetic analysis and provide accordingly differentiated treatment.(1,2) Standard In recent years, it has been reported that the frequency of DNAmethylation regulatory gene mutations – mutations of the genes that regulate ge…”
BackgroundCEBPE expression is an independent prognostic factor for acute myeloid leukemia
Li, K., Du, Y., Wei, D., & Zhang, F. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1944-x · Cited by 20
Pahl, A. M. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.1.43 · Cited by 17
RetractedUbiquitin-mediated proteasomal degradation in normal and malignant hematopoiesis
Heuzé, M. L., Lamsoul, I., Moog‐Lutz, C., & Lutz, P. G. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.011 · Cited by 18
Sanders, M. A., Verhaak, R. G. W., Geertsma-Kleinekoort, W. M. C., Abbas, S., Horsman, S., van der Spek, P. J., Löwenberg, B., & Valk, P. J. M. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-41 · Cited by 17
“Biotin-labeled cRNA of the same AML samples was hybridized on Affymetrix HG-U133 plus 2.0 GeneChips, as described elsewhere [34].”
MethodInfluentialSelf-citationMicroarrays to Identify New Therapeutic Strategies for Cancer
Sears, C., & Armstrong, S. A. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)96003-5 · Cited by 17
Lusa, L., McShane, L. M., Radmacher, M. D., Shih, J. H., Wright, G. W., & Simon, R. M. (2006) · Statistics in Medicine · doi:10.1002/sim.2598 · Cited by 21
“Introduction A frequent goal in gene expression microarray clinical studies is to develop a multivariate classifier of disease outcome [1-9].”
BackgroundXu, Y., Wang, P., Li, M., Wu, Z., Li, X., Shen, J., & Xu, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111054 · Cited by 17
Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
Guo, M., Chan, H. M. T., Zhou, Q., An, Ö., Li, Y., Song, Y., Tan, Z. H., Ng, H. E. V., Peramangalam, P. S., Tan, Z. Q., et al. (2023) · Blood · doi:10.1182/blood.2022015830 · Cited by 24
Day, R. B., Hickman, J. A., Xu, Z., Katerndahl, C. D. S., Ferraro, F., Ramakrishnan, S. M., Erdmann-Gilmore, P., Sprung, R. W., Mi, Y., Townsend, R. R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci176311 · Cited by 18
“AMLs with these fusions have distinct DNA methylation patterns (43–45), distinct gene expression profiles (43, 46), distinct proteomic signatures (47), different common cooperating mutations (43, 48–52), and different clinical phenotypes (53–59).”
BackgroundSaha, H. R., Kaneda‐Nakashima, K., Shimosaki, S., Suekane, A., Sarkar, B., Saito, Y., Ogoh, H., Nakahata, S., Inoue, K., Watanabe, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32205-8 · Cited by 16
Mollo, N., Aurilia, M., Scognamiglio, R., Zerillo, L., Cicatiello, R., Bonfiglio, F., Pagano, P., Paladino, S., Conti, A. M. F., Nitsch, L., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.824922 · Cited by 19
Lai, C. K., Moon, Y., Kuchenbauer, F. C., Starzcynowski, D. T., Argiropoulos, B., Yung, E., Beer, P. A., Schwarzer, A., Sharma, A., Park, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112671 · Cited by 16
“High MN1 expression has been associated with both acute myeloid and lymphoid leukemias [19] as well as other AML characteristics such as inv(16) [20] or overexpression of EVI-1 [21].”
BackgroundClinical proteomics of myeloid leukemia
Hjelle, S. M., Forthun, R. B., Haaland, I., Reikvam, H., Sjøholt, G., Bruserud, Ø., & Gjertsen, B. T. (2010) · Genome Medicine · doi:10.1186/gm162 · Cited by 17
“Nevertheless, approximately 50% of AML patients lack cytogenetic aberrations; because of this, gene expression profiles, DNA methylation patterns, micro RNA expression, protein production, chemokine production, and signal transduction responses have been used in subclassification [11,12,15,16].”
Methodvan Lierop, P. P. E., Swagemakers, S. M. A., de Bie, C. I., Middendorp, S., van Baarlen, P., Samsom, J. N., van IJcken, W. F. J., Escher, J. C., van der Spek, P. J., & Nieuwenhuis, E. E. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079549 · Cited by 16
“[16] In short, raw intensity values of all samples were normalized by background correction and quantile normalization using the version 6.”
BackgroundMethodBartlett, T. E., Jones, A., Goode, E. L., Fridley, B. L., Cunningham, J. M., Berns, E. M. J. J., Wik, E., Salvesen, H. B., Davidson, B., Trope, C. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143178 · Cited by 16
“Grouping genes with similar experimental measurements by using clustering methodology is well established as an effective approach for determining clinically relevant prognostic markers [17, 18].”
MethodNF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B
Zhou, J., Chooi, J.-Y., Ching, Y. Q., Quah, J. Y., Toh, S. H. M., Ng, Y., Tan, T. Z., & Chng, W. J. (2018) · World Journal of Stem Cells · doi:10.4252/wjsc.v10.i4.34 · Cited by 17
Arsenic trioxide induces the apoptosis and decreases NF‑κB expression in lymphoma cell lines
Zhong, L., Xu, F., & Chen, F. (2018) · Oncology Letters · doi:10.3892/ol.2018.9424 · Cited by 18
“Apoptosis, a programmed cell death, exerts a notable role by allowing cells to respond appropriately to environmental stimuli (6).”
Burnett, A. K. (2005) · Wiley eBooks · doi:10.1002/9780470987056.ch31 · Cited by 16
Isobe, T., Kuciński, I., Barile, M., Wang, X., Hannah, R., Bastos, H. P., Chabra, S., Vijayabaskar, M. S., Sturgess, K., Williams, M., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100426 · Cited by 19
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Gui, G., Ravindra, N., Hegde, P. S., Andrew, G. M., Mukherjee, D., Wong, Z. C., Auletta, J. J., Chaer, F. E., Chen, E. C., Chen, Y., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02447-4 · Cited by 16
New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy
Khan, I., Altman, J. K., & Licht, J. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0313 · Cited by 16
“Gene-Expression Profiling-Early gene expression profiling (GEP) of AML identified molecular subgroups with distinct gene-expression signatures (11).”
Genomics of Pulmonary Arterial Hypertension: Implications for Therapy
Geraci, M. W., Bull, T. M., & Tuder, R. M. (2009) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.08.001 · Cited by 15
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.